Drug intelligence / Profile preview

SND-635

Development stage: Preclinical
Lead developer: Floratek Pharma
Modality: Small Molecules

Overview

SND-635 is a first-in-class small molecule inhibitor targeting the nuclear receptor subfamily 4 group A member 1 (NR4A1), also known as Nur77. Developed by Floratek Pharma, the compound is derived from plant sources and is currently in the IND-enabling stage of development. SND-635 is being investigated for the treatment of solid tumors, specifically lung cancer and duodenal cancer. NR4A1 is a transcription factor that is frequently overexpressed in various malignancies, where it promotes cell survival, proliferation, and migration. By inhibiting NR4A1, SND-635 aims to disrupt these oncogenic pathways and induce apoptosis in cancer cells.

Other names: SND 635SND635SND-635

Targets

NR4A1 (Nuclear receptor subfamily 4 group A member 1)

Beyond the preview

Go deeper on SND-635.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SND-635.

Explore the full profile